Literature DB >> 21807423

Combination of B-type natriuretic peptide and minute ventilation/carbon dioxide production slope improves risk stratification in patients with diastolic heart failure.

Jing Yan1, Shi-Jin Gong, Li Li, Hai-Yan Yu, Hai-Wen Dai, Jin Chen, Cheng-Wu Tan, Qiang-Hong Xv, Guo-Long Cai.   

Abstract

BACKGROUND: Recent studies demonstrated that the minute ventilation/carbon dioxide production (VE/VCO(2)) slope more powerfully predicted mortality, hospitalization, or both than peak oxygen consumption (VO(2)) in systolic heart failure. However, the prognostic values of these two parameters in diastolic heart failure remained unclear.
METHODS: The patients with diastolic heart failure were recruited from April 2006 to May 2007, and underwent cardiopulmonary exercise testing. Plasma BNP concentration was measured using Triage BNP immunoassay method.
RESULTS: Of the 224 patients enrolled, mean values for age and New York Heart Association (NYHA) class were 68.8 ± 9.0 years and 2.38 ± 0.53, respectively. During the mean follow-up of 30 months, 57 patients died (36 from cardiovascular death). Univariate Cox regression analysis showed that age, NYHA class, atrial fibrillation, diabetes mellitus, left ventricular diastolic dysfunction, peak VO(2), VE/VCO(2) slope, and plasma BNP were significantly associated with mortality. Multivariate analysis revealed that plasma BNP, VE/VCO(2) slope, and age remained independent predictors for cardiovascular and all-cause mortalities, with the strongest prognostic power of plasma BNP (χ(2) ≥ 31.4, P < 0.001). In addition to plasma BNP and clinical predictors, the VE/VCO(2) slope could provide independent and incremental prognostic value of cardiovascular (χ(2) = 60.6 vs 51.7; P = 0.009) and all-cause mortalities (χ(2) = 62.8 vs 54.2; P = 0.015) with increased χ(2) value of Cox regression model.
CONCLUSION: In diastolic heart failure, plasma BNP is the strongest predictor of mortality, and VE/VCO(2) slope provides independent and additive prognostic information, which suggests that combination of plasma BNP and VE/VCO(2) slope can improve risk stratification.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807423     DOI: 10.1016/j.ijcard.2011.07.017

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Pulmonary Limitations in Heart Failure.

Authors:  Ivan Cundrle; Lyle J Olson; Bruce D Johnson
Journal:  Clin Chest Med       Date:  2019-06       Impact factor: 2.878

2.  Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project.

Authors:  Ali Shafiq; Clinton A Brawner; Heather A Aldred; Barry Lewis; Celeste T Williams; Christina Tita; John R Schairer; Jonathan K Ehrman; Mauricio Velez; Yelena Selektor; David E Lanfear; Steven J Keteyian
Journal:  Am Heart J       Date:  2016-01-12       Impact factor: 4.749

3.  Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction.

Authors:  Wilson Nadruz; Erin West; Morten Sengeløv; Mário Santos; John D Groarke; Daniel E Forman; Brian Claggett; Hicham Skali; Amil M Shah
Journal:  J Am Heart Assoc       Date:  2017-10-31       Impact factor: 5.501

4.  Impact of pericardiectomy on exercise capacity and sleep of patients with chronic constrictive pericarditis.

Authors:  Dirceu Thiago Pessoa de Melo; Flavia Baggio Nerbass; Ana Luiza Carrari Sayegh; Francis Ribeiro de Souza; Viviane Tiemi Hotta; Vera Maria Curi Salemi; Félix José Alvarez Ramires; Ricardo Ribeiro Dias; Geraldo Lorenzi-Filho; Charles Mady; Fábio Fernandes
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

5.  Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum.

Authors:  Jingyi Gong; Renata R T Castro; Jesse P Caron; Camden P Bay; Jon Hainer; Alexander R Opotowsky; Mandeep R Mehra; Bradley A Maron; Marcelo F Di Carli; John D Groarke; Anju Nohria
Journal:  ESC Heart Fail       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.